No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ACHIEVE study finds hearing aids cut cognitive decline by 48%
The study examined 977 adults from sites across four US states and found that the use of a hearing aid with patients at risk of cognitive decline slowed loss of cognitive abilities.
Akouos reports positive data from gene therapy trial for hearing loss
Initial results from the clinical trial indicate that AK-OTOF gene therapy restored hearing in patients with profound loss.
Frequency’s FX-322 improves hearing function in trial subjects
Biotechnology company Frequency Therapeutics has reported positive data from a Phase I/II clinical trial of investigational drug FX-322 intended for hearing restoration.
Regeneron’s gene therapy triumphs twice, restoring hearing in children
The two children with rare genetic otoferlin hearing loss enrolled in the Phase I/II trial for Regeneron’s gene therapy observed improvements in hearing.
Frequency treats first patients in Phase I/II trial of FX-322
Frequency Therapeutics has treated the first patients in a Phase l/ll clinical trial to investigate the safety of FX-322 for the treatment of patients with sensorineural hearing loss.
Otologic begins Phase I trial of HNPN-1010 to treat hearing disorders
US-based Otologic Pharmaceutics (OPI) has started Phase I clinical trial of its lead product candidate HNPN-1010 to treat acute sensorineural hearing loss.
Sensorion gets go ahead to launch hearing loss gene therapy trial
The Audiogene trial will feature paediatric patients aged six to 31 months in a bid to address early-stage hearing loss.
Ten children born deaf can now hear after Refreshgene trial
Refreshgene announced data at the ASCGT Conference 2024 where Regeneron also boasted positive data in a gene therapy hearing loss trial.
Frequency’s Phase IIa hearing loss trial shows no benefit versus placebo
Day-90 data from a Phase IIa study of four dosing regimens of Frequency Therapeutics’ hearing loss treatment FX-322 in subjects with mild to moderately severe sensorineural hearing loss (SNHL) “did not demonstrate improvements in hearing measures versus placebo”, according to a company statement.
Sensorion's sudden sensorineural hearing loss asset fails Phase II test
The asset failed to meet the primary goal of 15 decibels, a substantial improvement in pure tone audiometry in the affected ear from baseline.
Frequency doses first patient in Phase Ib sensorineural hearing loss trial
The company plans to report clinical data from the trial in the second half of next year.
Sensorion's SENS-401 meets secondary endpoints in Phase IIa hearing trial
Sensorion has reported that its hearing loss drug candidate SENS-401 has met secondary endpoints in a phase IIa proof of concept trial.
Sensorion's Phase I/II gene therapy trial to continue with DMC recommendation
The DMC's decision comes after assessing the first dose level's safety in six to 31-month-aged children.
Acousia given go ahead for hearing loss Phase II trial
The German company has been given the green light to proceed with Phase II clinical trials for ACOU085 to treat hearing loss.
Lower Covid-19 vaccination rates in deaf and blind Americans
According to the 2019 American Community Survey (ACS) by Cornell University, approximately 7.5 million Americans have a visual disability, and 11.6 million Americans have a hearing disability.
Acousia begins enrolment in cisplatin-induced hearing loss drug trial
Preclinical models have shown that ACOU085 has the potential to significantly reduce hearing loss caused by cisplatin.
MHRA authorises Decibel’s CTA for trial of DB-OTO in paediatric patients
DB-OTO is being developed by Decibel, in partnership with Regeneron Pharmaceuticals.
Sound Pharmaceuticals concludes Phase III Meniere’s disease therapy trial
Interim topline results from the RCT trial are anticipated to be presented this quarter.
Sensorion’s SENS-401 shows favourable safety profile in ototoxicity
Sensorion is also evaluating SENS-401 in patients to prevent residual hearing loss following cochlear implantation.
Sensorion completes first cohort enrolment in Phase I/II gene therapy trial
The trial is structured with two cohorts receiving different doses and an expansion cohort at the selected dose.